loading...| Preferred Name |
Denosumab |
|
| Synonyms |
Denosumab Biosimilar MW032 Denosumab Biosimilar QL1206 Denosumab Biosimilar TK-006 AMG 162 AMG-162 DENOSUMAB Denosumab Prolia TK-006 Xgeva denosumab |
|
| Definitions |
A fully human monoclonal antibody directed against the receptor activator of nuclear factor kappa beta ligand (RANKL) with antiosteoclast activity. Denosumab specifically binds to RANKL and blocks the interaction of RANKL with RANK, a receptor located on osteoclast cell surfaces, resulting in inhibition of osteoclast activity, a decrease in bone resorption, and a potential increase in bone mineral density. RANKL, a protein expressed by osteoblastic cells, plays an important role in osteoclastic differentiation and activation. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C61313 |
|
| Accepted_Therapeutic_Use_For |
Osteolytic Bone Metastases of Solid Tumors |
|
| ALT_DEFINITION |
A type of monoclonal antibody being studied in the treatment of multiple myeloma (a cancer that forms in bones) and in the prevention and treatment of bone metastases (cancer that has spread to bone from another organ). Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. AMG 162 binds to the protein RANKL and helps keep bone from breaking down. |
|
| CAS_Registry |
615258-40-7 |
|
| code |
C61313 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C179531 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923 |
|
| Contributing_Source |
CTRP FDA GDC HemOnc PCDC |
|
| DEFINITION |
A fully human monoclonal antibody directed against the receptor activator of nuclear factor kappa beta ligand (RANKL) with antiosteoclast activity. Denosumab specifically binds to RANKL and blocks the interaction of RANKL with RANK, a receptor located on osteoclast cell surfaces, resulting in inhibition of osteoclast activity, a decrease in bone resorption, and a potential increase in bone mineral density. RANKL, a protein expressed by osteoblastic cells, plays an important role in osteoclastic differentiation and activation. |
|
| Display_Name |
Denosumab |
|
| FDA_UNII_Code |
4EQZ6YO2HI |
|
| FULL_SYN |
Denosumab Biosimilar MW032 Denosumab Biosimilar QL1206 Denosumab Biosimilar TK-006 AMG 162 AMG-162 DENOSUMAB Denosumab Prolia TK-006 Xgeva denosumab |
|
| Has_Target | ||
| Is_Value_For_GDC_Property | ||
| label |
Denosumab |
|
| Legacy Concept Name |
Densosumab |
|
| Maps_To |
Denosumab |
|
| NCI_Drug_Dictionary_ID |
481348 |
|
| PDQ_Closed_Trial_Search_ID |
481348 |
|
| PDQ_Open_Trial_Search_ID |
481348 |
|
| Preferred_Name |
Denosumab |
|
| prefixIRI |
Thesaurus:C61313 |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C1690432 |
|
| subClassOf |